Skip to main content
. 2022 Sep 11;12(15):6665–6681. doi: 10.7150/thno.75444

Figure 8.

Figure 8

Pharmacokinetic studies of PMI-HIF1-1, SPMI2, and SPMI-HIF2-1. (A) Blood concentrations of PMI-HIF1-1, SPMI2, and SPMI-HIF2-1 at 0.5, 1, 2, 4, 6, 10, 24, and 48 h. (B-D) AUC, MRT, and half-time values of PMI-HIF1-1, SPMI2, and SPMI-HIF2-1. Male Institute of Cancer Research (ICR) mice (18-22 g) were divided into three groups (n = 5 mice/group): PMI-HIF1-1, SPMI2, and SPMI-HIF2-1. The peptides (1.8 mg/kg) were individually dosed in mice intravenously via tail vein injection. Blood samples were collected from the orbital venous plexus at 0, 0.5, 1, 2, 4, 6, 10, 24, and 48 h.